Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - emtricitabine, quantity: 200 mg; efavirenz, quantity: 600 mg; tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium metabisulfite; hyprolose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; ferric oxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - tenofovir disoproxil/ emtricitabine/ efavirenz mylan 300/200/600 is indicated for the treatment of hiv infected adults over the age of 18 years.,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts in controlled studies of viread, emtriva and stocrin in treatment-na?ve and treatment experienced adults.

Émirats arabes unis - anglais - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

unicare medical trading l.l.c saudi arabia - 30's (10's blister x 3) - tablet - 10 mg/tablet - central nervous system-dementia

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - chlorpromazine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; colloidal anhydrous silica; hypromellose; macrogol 200; magnesium stearate; titanium dioxide; purified water; industrial methylated spirit - 1. treatment of acute functional psychosis (eg schizophrenia, mania or psychotic depression). 2. long-term treatment of schizophrenia. 3. short-term treatment of agitation and severe depression. 4. severe behavioural disturbances, as can be found in some children with mental retardation or autism, including the treatment of self-injurious and aggressive behaviour or overactivity. use of chlorpromazine should be in conjunction with an appropriate non-pharmacological management program and long-term use should only be carried out under the supervision of a physician experienced in the management of psychotic disorders in children. 5. in the management of terminal illness to enhance the effect of analgesics and to control nausea and vomiting. 6. control of intractable hiccough.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - chlorpromazine hydrochloride, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; colloidal anhydrous silica; hypromellose; macrogol 200; magnesium stearate; titanium dioxide; purified water; industrial methylated spirit - 1. treatment of acute functional psychosis (eg schizophrenia, mania or psychotic depression). 2. long-term treatment of schizophrenia. 3. short-term treatment of agitation and severe depression. 4. severe behavioural disturbances, as can be found in some children with mental retardation or autism including the treatment of self-injurious and aggressive behaviour or overactivity. use of chlorpromazine should be in conjunction with an appropriate non-pharmacological management program and long-term use should only be carried out under the supervision of a physician experienced in the management of psychotic disorders in children. 5. in the management of terminal illness to enhance the effect of analgesics and to control nausea and vomiting. 6. control of intractable hiccough.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - chlorpromazine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; colloidal anhydrous silica; hypromellose; macrogol 200; magnesium stearate; titanium dioxide; purified water; industrial methylated spirit - 1. treatment of acute functional psychosis (eg schizophrenia, mania or psychotic depression). 2. long-term treatment of schizophrenia. 3. short-term treatment of agitation and severe depression. 4. severe behavioural disturbances, as can be found in some children with mental retardation or autism, including the treatment of self-injurious and aggressive behaviour or overactivity. use of chlorpromazine should be in conjunction with an appropriate non-pharmacological management program and long-term use should only be carried out under the supervision of a physician experienced in the management of psychotic disorders in children. 5. in the management of terminal illness to enhance the effect of analgesics and to control nausea and vomiting. 6. control of intractable hiccough.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - promethazine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; magnesium stearate; maize starch; povidone; macrogol 200; titanium dioxide; indigo carmine; purified water; industrial methylated spirit - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria, contact dermatitis, and allergic reactions to insect bites and stings. upper respiratory tract: relief of excesive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis. nausea and vomiting: antiemetic in vomiting of various causes, including post-operative vomiting, irradiation sickness, drug induced nausea, and motion sickness. sedation: for short term use on the advice of a doctor or pharmacist.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - promethazine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; macrogol 200; maize starch; lactose monohydrate; hypromellose; titanium dioxide; indigo carmine; purified water; industrial methylated spirit - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria, contact dermatitis, and allergic reactions to insect bites and stings. upper respiratory tract: relief of excesive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis. nausea and vomiting: antiemetic in vomiting of various causes, including post-operative vomiting, irradiation sickness, drug induced nausea, and motion sickness. sedation: for short term use on the advice of a doctor or pharmacist.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 4 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; hypromellose; macrogol 3350; iron oxide yellow; lactose; titanium dioxide; macrogol 400; iron oxide red; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 64 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; hypromellose; lactose; macrogol 3350; lactose monohydrate; titanium dioxide; triacetin; indigo carmine aluminium lake; macrogol 400; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 32 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; iron oxide yellow; hypromellose; lactose; macrogol 3350; lactose monohydrate; titanium dioxide; triacetin; macrogol 400; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.